Until now, only bevacizumab has been FDA approved as a first- and second-line VEGF-targeted agent for CRC, although various novel agents are emerging, and some of them have been approved for second-line treatment of CRC. The gene discussed is VEGFA; the disease is colorectal carcinoma.